Showing 4321-4330 of 5627 results for "".
- Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weekshttps://modernod.com/news/novartis-announces-positive-results-from-phase-3-trials-of-beovu-in-dme-including-dosing-intervals-up-to-16-weeks/2479452/Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evalu
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- Alcon to Launch TOTAL30 as the First Monthly Replacement, Water Gradient Contact Lenshttps://modernod.com/news/alcon-to-launch-total30-as-the-first-monthly-replacement-water-gradient-contact-lens/2479449/Alcon announced plans to launch TOTAL30, the first-and-only monthly replacement, water gradient lens. Using Alcon’s proprietary water gradient material first introduced with DAILIES TOTAL1 contact lenses, TOTAL30 delivers a premium wearing experience for reusable contact lens wearers, according t
- Retina Consultants of America Expands Into North Carolinahttps://modernod.com/news/retina-consultants-of-america-expands-into-north-carolina/2479446/Physician management services organization Retina Consultants of America (RCA) had added North Carolina Retina Associates (NC Retina Associates) to its national consortium. Terms of the deal were not disclosed. The addition of NC Retina Associates marks RCA’s first entry into the No
- Oyster Point Pharma Announces License Agreement With Ji Xing Pharmaceuticals in Greater Chinahttps://modernod.com/news/oyster-point-pharma-announces-license-agreement-with-ji-xing-pharmaceuticals-in-greater-china/2479438/Oyster Point Pharma announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for the treatment of signs and symptoms of dry eye disease for patients in Greater Chi
- Eyevensys Raises $12M in a Series B Plus Funding Roundhttps://modernod.com/news/eyevensys-raises-12m-in-a-series-b-plus-funding-round/2479435/Eyevensys announced it has raised $12 million in a Series B Plus funding round. Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round. The financing will support Eyevensys’ accelerated development of its EYS809 program for the tr
- IrisVision Names Naeem Kayani President & Chief Operating Officerhttps://modernod.com/news/irisvision-names-naeem-kayani-president-chief-operating-officer/2479431/IrisVision announced the addition of Naeem Kayani to serve as President and Chief Operating Officer. Launched in 2017, IrisVision’s flagship consumer product employs breakthrough, smart software lens technology that leverages functional areas of the eyes to restore vision instantly. Design
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Oculus Supports IMI in Raising Myopia Awarenesshttps://modernod.com/news/oculus-supports-imi-in-raising-myopia-awareness/2479430/Oculus has joined the International Myopia Institute (IMI) in tackling myopia awareness and will support the IMI activities to advance the research of myopia to prevent future vision impairment and blindness. “We are delighted about the cooperation. Our mission at Oculus is to support eye
- RxSight Announces Pricing of Initial Public Offeringhttps://modernod.com/news/rxsight-announces-pricing-of-initial-public-offering/2479423/RxSight announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16 per share. The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and